Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field, showing how they are being used as key levers for ADC drug developers to ...

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has become one of the ...